CA2099270A1 - Derives quinoxaliniques a affinite pour les recepteurs du quisqualate - Google Patents

Derives quinoxaliniques a affinite pour les recepteurs du quisqualate

Info

Publication number
CA2099270A1
CA2099270A1 CA002099270A CA2099270A CA2099270A1 CA 2099270 A1 CA2099270 A1 CA 2099270A1 CA 002099270 A CA002099270 A CA 002099270A CA 2099270 A CA2099270 A CA 2099270A CA 2099270 A1 CA2099270 A1 CA 2099270A1
Authority
CA
Canada
Prior art keywords
acid
dioxo
nitro
alkyl
tetrahydroquinoxalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002099270A
Other languages
English (en)
Inventor
Andreas Huth
Ralph Schmiechen
Ilse Beetz
Ingrid Schumann
Lechoslaw Turski
Peter Andreas Loschmann
David Norman Stephens
Dieter Seidelmann
Martin Kruger
Dieter Rahtz
Peter Holscher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4135871A external-priority patent/DE4135871A1/de
Application filed by Individual filed Critical Individual
Publication of CA2099270A1 publication Critical patent/CA2099270A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/650952Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C07F9/650994Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002099270A 1991-10-26 1992-10-25 Derives quinoxaliniques a affinite pour les recepteurs du quisqualate Abandoned CA2099270A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4135871A DE4135871A1 (de) 1991-10-26 1991-10-26 Chinoxalinderivate, deren herstellung und verwendung in arzneimitteln
DEP4135871.6 1991-10-26
DE4224200 1992-07-17
DEP4224200.2 1992-07-17

Publications (1)

Publication Number Publication Date
CA2099270A1 true CA2099270A1 (fr) 1993-04-27

Family

ID=25908683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002099270A Abandoned CA2099270A1 (fr) 1991-10-26 1992-10-25 Derives quinoxaliniques a affinite pour les recepteurs du quisqualate

Country Status (17)

Country Link
EP (1) EP0565683A1 (fr)
JP (1) JP3258008B2 (fr)
KR (1) KR100262371B1 (fr)
CN (1) CN1038840C (fr)
AU (1) AU664212B2 (fr)
CA (1) CA2099270A1 (fr)
CZ (1) CZ286351B6 (fr)
FI (1) FI932959A0 (fr)
HU (1) HUT64756A (fr)
IL (1) IL103538A (fr)
NO (1) NO304693B1 (fr)
NZ (1) NZ244896A (fr)
PL (1) PL171125B1 (fr)
PT (1) PT101004B (fr)
RU (1) RU2117663C1 (fr)
SK (1) SK281518B6 (fr)
WO (1) WO1993008173A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773439A (en) * 1994-06-22 1998-06-30 Basf Aktiengesellschaft Amido-quinoxalinediones, the preparation and use thereof
US5895824A (en) * 1995-06-09 1999-04-20 Basf Aktiengesellschaft Preparation of polyether polyols containing aromatics
US6277850B1 (en) 1996-06-21 2001-08-21 Abbott Laboratories Pyrrolyl quinoxalindiones their production and use as AMPA receptor antagonists

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162491D0 (da) * 1991-09-20 1991-09-20 Novo Nordisk As Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
DE4314592A1 (de) * 1993-04-28 1994-11-03 Schering Ag Benzo(f)chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
IL109397A0 (en) * 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
GB9419318D0 (en) * 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
US6096743A (en) * 1994-09-27 2000-08-01 Yamanouchi Pharmaceuticals Co., Ltd. 1,2,3,4-tetrahydroquinoxalinedione derivative
DE4439493A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
DE4439492A1 (de) * 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
DE19545251A1 (de) * 1995-11-24 1997-05-28 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
TW448171B (en) * 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
DE19728326A1 (de) * 1997-06-27 1999-01-07 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
EP0900567A3 (fr) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
FR2769309B1 (fr) 1997-10-08 2001-06-15 Oreal Composition de teinture d'oxydation des fibres keratiniques comprenant un derive d'aminoacide en tant que base d'oxydation et nouveaux derives d'aminoacides
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118982A1 (fr) * 1983-02-01 1984-09-19 Sumitomo Chemical Company, Limited Composés organo-phosphorés de la quinoxalinone, leur production et utilisation
NO179551C (no) * 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
DK69790D0 (da) * 1990-03-16 1990-03-16 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling af anvendelse

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773439A (en) * 1994-06-22 1998-06-30 Basf Aktiengesellschaft Amido-quinoxalinediones, the preparation and use thereof
US5895824A (en) * 1995-06-09 1999-04-20 Basf Aktiengesellschaft Preparation of polyether polyols containing aromatics
US6277850B1 (en) 1996-06-21 2001-08-21 Abbott Laboratories Pyrrolyl quinoxalindiones their production and use as AMPA receptor antagonists

Also Published As

Publication number Publication date
NO932344D0 (no) 1993-06-25
FI932959A (fi) 1993-06-24
NZ244896A (en) 1995-07-26
NO932344L (no) 1993-06-25
HU9301877D0 (en) 1993-09-28
PT101004A (pt) 1994-01-31
IL103538A (en) 2001-07-24
PT101004B (pt) 1999-10-29
RU2117663C1 (ru) 1998-08-20
IL103538A0 (en) 1993-03-15
PL171125B1 (pl) 1997-03-28
JP3258008B2 (ja) 2002-02-18
FI932959A0 (fi) 1993-06-24
KR100262371B1 (ko) 2000-08-01
CZ286351B6 (cs) 2000-03-15
KR930703271A (ko) 1993-11-29
AU2889492A (en) 1993-05-21
WO1993008173A1 (fr) 1993-04-29
CN1038840C (zh) 1998-06-24
NO304693B1 (no) 1999-02-01
CZ138793A3 (en) 1994-01-19
JPH06503583A (ja) 1994-04-21
AU664212B2 (en) 1995-11-09
SK281518B6 (sk) 2001-04-09
EP0565683A1 (fr) 1993-10-20
HUT64756A (en) 1994-02-28
CN1072929A (zh) 1993-06-09
PL299929A1 (en) 1994-04-05
SK72793A3 (en) 1993-10-06

Similar Documents

Publication Publication Date Title
CA2099270A1 (fr) Derives quinoxaliniques a affinite pour les recepteurs du quisqualate
US5750525A (en) Quinoxalinedione derivatives, their production and use in pharmaceutical agents
CA1321587C (fr) Composes de type quinoxalidine, leur preparation et leur utilisation
US6143733A (en) Quinoxalinedione derivatives, their production and use in pharmaceutical agents
US6288065B1 (en) Quinoxaline-carboxylic acid derivatives
WO1996040649A1 (fr) Derives de la quinoxaline 2,3-dione substitues par des derives d'acides amines, utilises comme antagonistes des recepteurs du glutamate
US6001832A (en) [1,2,4]triazolo[4,3-a]quinoxalinone derivatives, their preparation and use
US5750526A (en) Pyrido 1,2,3-DE!quinoxaline derivatives, process for their production and their use in pharmaceutical agents
CA2161426A1 (fr) Derives de la benzo[f]quinoxalinedione; preparation et utilisation dans des medicaments
JPH10506620A (ja) 〔1,2,4〕トリアゾロ〔4,3−a〕キノキサリノン誘導体、それらの調製方法及び使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued